Compare HIO & RXST Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | HIO | RXST |
|---|---|---|
| Founded | 1993 | 1997 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Finance/Investors Services | Biotechnology: Electromedical & Electrotherapeutic Apparatus |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 368.0M | 366.3M |
| IPO Year | N/A | 2021 |
| Metric | HIO | RXST |
|---|---|---|
| Price | $3.81 | $8.03 |
| Analyst Decision | | Hold |
| Analyst Count | 0 | 11 |
| Target Price | N/A | ★ $11.40 |
| AVG Volume (30 Days) | 305.3K | ★ 1.1M |
| Earning Date | 01-01-0001 | 02-27-2026 |
| Dividend Yield | ★ 10.33% | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $142,085,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $2.88 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ 10.75 |
| 52 Week Low | $3.52 | $6.32 |
| 52 Week High | $4.03 | $33.08 |
| Indicator | HIO | RXST |
|---|---|---|
| Relative Strength Index (RSI) | 60.81 | 33.98 |
| Support Level | $3.76 | $7.73 |
| Resistance Level | $3.79 | $8.51 |
| Average True Range (ATR) | 0.02 | 0.51 |
| MACD | 0.01 | -0.03 |
| Stochastic Oscillator | 98.89 | 13.55 |
Western Asset High Income Oppor Fd Inc is a diversified closed-end management investment company. The company's primary objective is to seek high current income and the secondary objective is capital appreciation. It invests a majority of its net assets in high-yield corporate debt securities and the rest in common stock equivalents, including options, warrants, and rights. The company invests in securities of companies from various sectors such as energy, technology, utilities, industrials, communications, finance, and capital goods among others.
RxSight Inc is a commercial-stage medical technology company dedicated towards improving the vision of patients following cataract surgery. It offers intraocular lens technology that enables doctors to customize and optimize visual acuity for patients after cataract surgery. The company operates and manages its business in one reportable segment, the research and development, manufacture and sale of light adjustable lenses and related capital equipment.